What is the role of intradetrusor onabotulinumtoxinA (OBA) in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS)?

Updated: Dec 04, 2020
  • Author: Eric S Rovner, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

Transurethral intradetrusor injection of onabotulinumtoxinA (OBA) coupled with therapeutic hydrodistention has been shown to be superior to hydrodistention alone in improving symptoms and bladder capacity in patients with interstitial cystitis. However, higher doses appear to increase the risk of postoperative voiding dysfunction and urinary retention. The use of intradetrusor OBA for this indication remains investigational. [99, 100, 101]

Multicenter trials investigating OBA use for refractory IC/BPS have shown significant benefit in a small number of patients, but overall no improvement in O'Leary-Sant scores. [102]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!